Results 221 to 230 of about 193,078 (253)
Some of the next articles are maybe not open access.
Journal of Clinical Oncology, 2014
35 Background: In a randomized controlled trial of men with castration-resistant prostate cancer (CRPC) and bone metastases, denosumab was superior to zoledronic acid (ZA) for reducing skeletal-related events (SRE, defined as pathological fracture, surgery or radiation to bone [including the use of radioisotopes], or spinal cord compression) (Fizazi,
Matthew R. Smith +7 more
openaire +1 more source
35 Background: In a randomized controlled trial of men with castration-resistant prostate cancer (CRPC) and bone metastases, denosumab was superior to zoledronic acid (ZA) for reducing skeletal-related events (SRE, defined as pathological fracture, surgery or radiation to bone [including the use of radioisotopes], or spinal cord compression) (Fizazi,
Matthew R. Smith +7 more
openaire +1 more source
Analysis of Denosumab on Skeletal-Related Events in Patients With Advanced Breast Cancer
Clinical Journal of Oncology Nursing, 2015Bisphosphonates, which are also known as osteoclast modifiers, are the standard of care in the treatment of skeletal-related events (SREs) in patients with breast cancer with metastatic bone disease. SREs are frequently a complication of advanced breast cancer, and they greatly increase morbidity and mortality in these patients.
openaire +2 more sources
Minimally Invasive Treatment of Skeletal-Related Events
2023Amata Thongphetsavong Gautam +1 more
openaire +1 more source
PAMIDRONATE FOR THE PREVENTION OF SKELETAL- RELATED EVENTS IN MULTIPLE MYELOMA
International Journal of Technology Assessment in Health Care, 1999Multiple myeloma is a disorder of the bone marrow that is associated with bone pain and osteolytic lesions. These complications can lead to the development of pathologic fractures and severe patient morbidity. However, the results of a recent randomized trial in patients with multiple myeloma demonstrated that single 90 mg monthly doses of ...
openaire +2 more sources
Decreased incidence of skeletal-related events in mRCC
Nature Reviews Urology, 2014Takeshi Yuasa, Shinji Urakami
openaire +1 more source
The cost of treating skeletal-related events in patients with prostate cancer.
The American journal of managed care, 2008To examine the economic burden of skeletal-related events (SREs) and to assess the frequency of different types of SREs in this population.Retrospective claims analysis.Data were obtained from i3's Lab Rx Database from May 1, 2000, through March 31, 2005. Patients included had at least 2 claims with a diagnosis of prostate cancer, at least 2 subsequent
Maureen J, Lage +3 more
openaire +1 more source
Epigenetics and Regenerative Medicine: Neural and Skeletal Muscle Perspectives
Medical Epigenetics, 2016Daniela Palacios
exaly